Drug discovery course from Harvard Medical School

I have always enjoyed learning — going back to my early school days to the graduate program. In today’s rapidly evolving landscape, staying up to date is essential to stay current. Especially when working at the intersection of AI, biology, and drug discovery. It is easy to go deep in one area and miss important context from the broader picture.

At SandboxAQ, we encourage continuous learning and cross-disciplinary understanding.

I’m excited to share that I’ve completed the course “Drug Discovery and Development” from HMX – Harvard Medical School.

This course provided a comprehensive overview of the end-to-end therapeutic development pipeline, starting from target identification, overview of drug modalities (small molecule, RNA, biologics), Target Product Profiles (TPPs), to preclinical work including clinical trials, and regulatory considerations.

For me, one of the biggest takeaways was to gain a clearer understanding of the language of modern drug development. As a computational scientist, bridging the gap between data science, biology, and clinical development is really important. This course helped strengthen that connection and improve how I collaborate with experimental teams and communicate with stakeholders.

I am looking forward to applying these insights for my ongoing work in AI-driven drug discovery and biomedical knowledge systems.

I would like to recommend this course to anyone interested in understanding how modern therapeutics move from idea to the clinic.